Competitive Intelligence Brief — MASH In-Market, US Market

The Lead and the Clock

Rezdiffra owns the only approved MASH market in the US — for now. The advantage is real, time-limited, and indefensible by spend once Novo's semaglutide arrives.

Madrigal holds a position no competitor can claim today: the first and only FDA-approved therapy for MASH with moderate-to-advanced fibrosis. But the moat is built on time, not mechanism — and the clock runs out when the GLP-1 class arrives. Semaglutide enters MASH carrying the most commercially powerful franchise in metabolic medicine and a weight-loss halo no liver-specific agent can match. A defense built on detailing and awareness is lost before it starts.

Novo can out-resource Madrigal on field force and direct-to-consumer spend by roughly an order of magnitude; that contest is unwinnable. The one advantage Madrigal can own is structural — preferred payer coverage and the fibrosis-regression clinical position, locked while Rezdiffra is still the only option a payer can cover. Coverage written now, against no competitor, is the asset that survives 2027.

Below, we map the competitive clock, the payer window, and the decisions Madrigal's commercial team needs to make before the class consolidates.

FDA-approved MASH therapy today — Rezdiffra (resmetirom), the entire approved market

~2027

Expected US entry of semaglutide in MASH — the first GLP-1 to challenge the category

~15×

Novo's quarterly GLP-1 sales relative to Madrigal's net product revenue — a spend war Madrigal cannot win

12–18 mo

Pre-entry window to lock payer coverage and the regression position before the class opens

What Your Team Needs Answered

Five commercial questions. Each section is built to answer one of them.

Structured by decision, not by topic. Every section produces a named output that feeds a specific call your team will have to make — on positioning, on access, on which cohorts to defend.

How large is the addressable MASH pool today — and which patients are reachably diagnosed, not just prevalent?

DeliversFunnel from prevalence to biopsy/NIT-confirmed F2–F3 · diagnosed-and-treated share · projection with diagnosis-rate sensitivity

Where does Rezdiffra's clinical position hold against a GLP-1 — and where does the weight-loss halo erode it?

DeliversMechanism map (THR-β vs GLP-1) · fibrosis-regression vs metabolic-endpoint comparison · prescriber-segment vulnerability read

What coverage has Rezdiffra secured — and what will payers require once a second option exists?

DeliversCurrent formulary and PA architecture · step-therapy exposure · coverage scenarios under a two-drug market

Where will semaglutide take share first — and which Rezdiffra cohorts are defensible?

DeliversEntry-cohort mapping (obese/diabetic MASH vs fibrosis-driven) · switch-risk segmentation · defensible-base estimate

What are the realistic share-retention scenarios at entry, Year 1, and Year 3 post-semaglutide?

DeliversThree-scenario retention model · ranked assumption drivers · revenue-at-risk sensitivity table

Scoped to Rezdiffra's label, your secured coverage, and the entry profile semaglutide is expected to carry — not the market in aggregate.

Scope Your Work

Inside the Brief

Eight sections. Every section structured around a named defensive decision.

What your team receives. Section scope, competitive agents, and patient cohorts are built around Rezdiffra's position and the expected entrant — not pulled from a generic MASH template.

AXLRx™ · Intelligence Brief · Competitive Intelligence

MASH — In-Market Defense Intelligence, US

Prepared for Madrigal US Commercial · Q2 2026 · 30 pages · Confidential

Contents

01The Strategic Casepp. 1–3
- The defensive posture recommended before semaglutide's entry — what to lock, what to concede, what to contest
- Pre-entry actions by function — market access, medical affairs, commercial — in order of urgency
- What secondary research resolves now vs. what requires primary investigation
02The Diagnosed Poolpp. 4–7
- Prevalence vs diagnosed vs biopsy/NIT-confirmed F2–F3 — the funnel that defines the real addressable base
- The diagnostic gate: where MASH patients are lost between primary care, endocrinology, and hepatology
- The epidemiological assumptions your team will be challenged on in the first defense review
03The Patient Funnelpp. 8–11
- Bottom-up build: prevalence → at-risk fibrosis → diagnosed → treated, with diagnosis-rate sensitivity
- Five-year projection — where diagnosis growth and a GLP-1 halo expand or shift the pool
- The three assumptions that drive 80% of the variance in the addressable estimate
04The Competitive Clockpp. 12–17
- THR-β vs GLP-1 mechanism: fibrosis regression vs metabolic and weight endpoints — where each wins
- Trial-level stack: MAESTRO-NASH vs ESSENCE, plus the FGF21 and pan-PPAR pipeline behind them
- What the landscape looks like post-2027 — semaglutide entry, lanifibranor, efruxifermin, pegozafermin
05The Access Architecturepp. 18–21
- Rezdiffra's secured coverage and PA criteria — what broad, restricted, and step-gated look like today
- The evidence standard payers will apply once a second option exists — and where it favours whom
- Gap analysis — where the coverage position strengthens the defense and where it is exposed
06The Prescriber Layerpp. 22–24
- The hepatology / endocrinology / primary-care split — who controls MASH prescribing and where the GLP-1 halo lands
- NASH/MASH guideline positions and what the field believes about thyroid-receptor vs incretin therapy
- Where prescribing influence concentrates and which segments are most switch-vulnerable
07The Retention Registerpp. 25–27
- Three share-retention scenarios — defend, erode, displace — built by cohort, not in aggregate
- The five inputs that drive variance: coverage lock, switch rate, label scope, diagnosis growth, entry timing
- Entry · Y1 · Y3 retained share and revenue-at-risk — with the lever each decision-maker controls
08Client Alignment Questionspp. 28–30
- Evidence gaps secondary research cannot close — and the primary work your team would need to commission
- Payer conversations that must begin 12–18 months pre-entry to avoid losing coverage exclusivity
- Decisions contingent on the ESSENCE outcome, semaglutide's label scope, and entry timing
— Source Annex — all PMIDs, ClinicalTrials.gov IDs, and live URLs pp. A1–A6

At a glance

30pages across 8 structured sections

5commercial questions answered

72hfrom scope confirmation to delivery

100%of figures cited to live source

Readout call included

All deliveries include a 30-minute call with your analyst — to walk through findings and identify what your team needs to resolve next.

What You Receive

Three outputs delivered within 72 hours. Each built for a different role in your commercial team.

The intelligence analysis, the working model, and the board summary — delivered together. Your defense lead, your commercial analyst, and your leadership team each get what they need.

Core Deliverable

PDF

PDF · ~30 pages

Intelligence Brief

Structured for sequential reading by your defense lead, medical affairs director, and market access team. Every exhibit sourced. Every conclusion frames a decision.

Executive summary — 3 pages, decision-level
Diagnosed-pool funnel and addressable base
Competitive clock — THR-β vs GLP-1 and the pipeline
Payer and reimbursement architecture
Prescriber landscape and switch-vulnerability map
Strategic open questions and evidence gaps
Source annex — all PMIDs and live URLs

XLS

Excel Workbook

Share-Retention Model

A live, editable model your commercial analyst can run sensitivities on without rebuilding. Assumptions are labelled and sourced throughout.

Bottom-up funnel — prevalence to treated F2–F3
Cohort splits by fibrosis stage and metabolic profile
Three retention scenarios with editable inputs
Revenue-at-risk model with coverage and entry timing
Sensitivity table — top 5 assumption levers

PPT

PowerPoint · Optional Add-on

Executive Deck

Five slides your leadership team can act on — for a defense review, board briefing, or pre-entry alignment session. Structured around decisions, not descriptions.

Market position — the only approved MASH therapy, today
Competitive threat — semaglutide's entry profile
Payer lock gap and what it requires now
Share-retention scenarios at entry · Y1 · Y3
Priority decisions and open questions

Sample Output

Exhibit 3 — Competitive landscape, US MASH.

Rezdiffra (Madrigal) shown as the client position. Mechanism and trial identifiers are public; quantitative share and revenue figures on this sample are illustrative and would be live-sourced and cited by PMID on a commissioned brief.

MASH Agent Competitive Map — US Market · Q2 2026 Sample · Illustrative

Agent (Sponsor)	Mechanism	Approval Status	Pivotal Trial	Fibrosis Endpoint	Weight / Metabolic	US Coverage	Share Est.
Rezdiffra (resmetirom)Madrigal · client position	THR-β agonist (oral)	Approved · Mar 2024	MAESTRO-NASH	Fibrosis improvement + NASH resolution	Modest	Broad (building)	~100%
Semaglutide 2.4 mgNovo Nordisk · challenger	GLP-1 receptor agonist (SC)	Filed · expected ~2027	ESSENCE (NCT04822181)	NASH resolution; fibrosis signal	Strong weight loss	Pre-approval	Entry cohort
LanifibranorInventiva	pan-PPAR agonist (oral)	Phase 3 · reads H2 2026	NATiV3	Pending	Metabolic	Pipeline	—
EfruxiferminAkero Therapeutics	FGF21 analog (SC)	Phase 3	SYNCHRONY	Pending	Metabolic + weight	Pipeline	—
Pegozafermin89bio	FGF21 analog (SC)	Phase 3	ENLIGHTEN	Pending	Metabolic + weight	Pipeline	—

Sources: Mechanisms and trial identifiers from FDA prescribing information (resmetirom) and ClinicalTrials.gov (ESSENCE NCT04822181, NATiV3, SYNCHRONY, ENLIGHTEN). MAESTRO-NASH: Harrison et al., NEJM 2024. Resmetirom FDA accelerated approval March 2024. NOTE: this is a draft sample page — share and revenue estimates shown are illustrative and have not been through the AXLRx live-source and audit gate.

Source Standard

Every figure is live-sourced before delivery. If a number cannot be verified, it does not appear.

The MASH competitive landscape is moving fast — Phase 3 readouts, a filed GLP-1, and evolving payer policy. It is exactly the field where AI confidently reproduces superseded trial data and outdated coverage criteria. AXLRx uses none of its own memory as a source. Every figure your team receives is verified against a live document at the time of writing.

A wrong number in front of your payer or your leadership team is not recoverable in the same meeting.

Every claim cited to a live PMID, ClinicalTrials.gov ID, or URL at point of writing — uncited claims are dropped, not estimated
PubMed metadata fetched live during authoring — model memory produces incorrect author and journal data even on correct PMIDs
Numeric cross-check: the specific figure must appear in the cited source, not merely be consistent with its topic
Independent audit pass after generation — broken links, unsourced claims, and numeric inconsistencies flagged before delivery
Drop gate: any figure that cannot clear the above is removed. No confidence tiers. No exceptions.

Questions

What commercial teams ask before commissioning.

Scope

How is this different from a syndicated market research report?

A syndicated report describes the MASH market. This frames the defensive decisions your team needs to make before semaglutide enters. Every section answers a named commercial question your defense lead or market access director will face. It is decision-ready intelligence, not background reading.

Scope

Can scope be adjusted for our position and the expected entrant?

Always. There is no generic MASH template. The competitive landscape is scoped to the agents Rezdiffra will actually face and the entry profile semaglutide is expected to carry. The payer analysis is built around your secured coverage, not a category average.

Delivery

How long does delivery take?

72 hours from scope confirmation. A 48-hour track is available for board presentations or due diligence deadlines. All deliveries include a 30-minute readout call — your analyst walks your team through findings and identifies what to resolve next.

Sourcing

Are the figures verified or recalled from AI training data?

Every figure is cited to a live PMID or URL at the point of writing — never from model memory. A numeric cross-check confirms the figure appears in the cited source. If it cannot be verified, it does not appear.

Format

Do we receive editable files or fixed PDFs?

The PDF is fixed. Your Excel share-retention model is fully editable — assumptions are labelled so your analyst can run sensitivities without rebuilding it. The PowerPoint deck is editable if commissioned as an add-on.

Process

What if we only need one section — the payer analysis or the competitive clock?

Scoped standalone sections are available. Tell us at intake which questions your team needs answered. A scoped section typically delivers in 24–36 hours and is priced by scope, not the full rate.

Commission Your Analysis

Tell us your position. Your team has the defense intelligence in 72 hours.

We build from your asset's clinical profile and secured coverage — mechanism, label scope, target cohort, and the entrant you are defending against. Scope confirmation takes one call.

Start Your Request

Or see a sample output to review the depth before committing.

Submit your asset profile

Drug, mechanism, label scope, target cohort, the entrant you are defending against. Five minutes via the intake form.

Scope confirmed in 24 hours

We confirm scope with your team, clarify any ambiguities, and lock delivery timing. One call or email exchange.

Your analysis, delivered in 72 hours

PDF intelligence document, Excel model, and optional executive deck — with a 30-minute readout call included.

Defending the only approved MASH therapy before the 2027 class opens.